EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment
JCO Precision Oncology - United States
doi 10.1200/po.17.00277
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2018
Authors
Publisher
American Society of Clinical Oncology (ASCO)